A new crystal form of aztreonam and its preparation method and application

By dissolving and back-soluble crystallization under specific conditions, a high water-soluble new crystal form of ammonia trenchon was prepared, which solved the problem of insufficient water solubility of the existing ammonia trenchonon and improved the bioavailability and medical value of the drug.

CN115504974BActive Publication Date: 2024-11-12TIANJIN UNIV +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202211188129.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-28
Publication Date
2024-11-12
Estimated Expiration
2042-09-28

AI Technical Summary

Technical Problem

The existing amphramide has poor water solubility, which affects the bioavailability of the drug and limits its application in oral and other routes of administration.

Method used

A new type of amphthalene crystal was developed, and one or two crystal forms with high water solubility were prepared by dissolving and back-dissolving crystallization under specific conditions. The specific steps include dissolving amphthalene in an organic solvent. Add a anti-solvent to perform lysis crystallization, and select an appropriate anti-solvent and temperature to obtain a new crystal form with high solubility.

Benefits of technology

It improves the solubility of amtroscopy in water, enhances its bioavailability, and makes it have higher medical value in drug applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115504974B_ABST
    Figure CN115504974B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of chemical medicine, and specifically relates to a new crystal form of aztreonam and a preparation method and application thereof. The new crystal form of aztreonam provided by the present invention includes crystal form one or crystal form two, and the X-ray powder diffraction pattern of the crystal form one is 8.6±0.1°, 9.3±0.1°, 11.2±0.1°, 16.8±0.1°, 17.6±0.1°, 18.6±0.1°, 20.9±0.1°, 21.5±0.1°, 23.3±0.1°, 24.5±0.1° at a diffraction angle 2θ. The X-ray powder diffraction pattern of the crystal form II has characteristic peaks at diffraction angles 2θ of 9.5±0.1°, 10.3±0.1°, 12.3±0.1°, 15.2±0.1°, 15.7±0.1°, 19.3±0.1°, 20.9±0.1°, 21.9±0.1°, 24.8±0.1°, 27.6±0.1°, and 31.8±0.1°. The new crystal form of aztreonam provided by the present invention has good water solubility, thereby improving its bioavailability and medical value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical medicine, and specifically relates to a new crystal form of aztreonam and a preparation method and application thereof. Background Art

[0002] The chemical name of Aztreonam is [2S-[2a,3b(Z)]]-2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxyethylidene]amino]oxy]-2-methylpropanoic acid, and its molecular formula is C 13 H 17 N5O8S2, with a molecular weight of 435.43, is a white crystalline powder having a structure as shown in formula (I):

[0003]

[0004] Aztreonam is a new type of β-lactam antibiotic of the monoamide ring class. It inhibits bacterial growth by binding to penicillin-binding protein. It is mainly used for sepsis, lower respiratory tract, urinary tract and skin and soft tissue infections caused by Enterobacteriaceae and Pseudomonas aeruginosa. Currently, there are four crystal forms of aztreonam on the market: α, β, γ and δ. The four crystal forms of aztreonam can be dissolved in N,N-dimethylformamide or dimethyl sulfoxide, slightly soluble in water, and its solubility is only 0.886g / L at 25°C. Oral aztreonam is basically not absorbed and is only suitable for intravenous drip, intravenous injection and intramuscular injection. The poor water solubility of the existing aztreonam seriously affects the bioavailability of the drug. Summary of the invention

[0005] In view of this, the present invention provides a new crystal form of aztreonam and a preparation method and application thereof. The new crystal form of aztreonam provided by the present invention has high water solubility and improves the bioavailability of the drug.

[0006] In order to solve the above technical problems, the present invention provides a new crystal form of aztreonam, wherein the new crystal form of aztreonam includes crystal form 1 or crystal form 2, and the X-ray powder diffraction pattern of the crystal form 1 has characteristic peaks at diffraction angles 2θ of 8.6±0.1°, 9.3±0.1°, 11.2±0.1°, 16.8±0.1°, 17.6±0.1°, 18.6±0.1°, 20.9±0.1°, 21.5±0.1°, 23.3±0.1°, and 24.5±0.1°;

[0007] The X-ray powder diffraction pattern of the crystal form II has characteristic peaks at diffraction angles 2θ of 9.5±0.1°, 10.3±0.1°, 12.3±0.1°, 15.2±0.1°, 15.7±0.1°, 19.3±0.1°, 20.9±0.1°, 21.9±0.1°, 24.8±0.1°, 27.6±0.1°, and 31.8±0.1°.

[0008] Preferably, the peak height and relative intensity corresponding to the diffraction angle 2θ in the X-ray powder diffraction pattern of the crystal form 1 are shown in Table 1:

[0009] Table 1 Peak height and relative intensity corresponding to diffraction angle 2θ

[0010] 2θ(°) Peak height Relative strength (%) 8.6±0.1° 29 15.6 9.3±0.1° 21 11.3 11.2±0.1° 103 55.4 16.8±0.1° 82 44.1 17.6±0.1° 27 14.5 18.6±0.1° 108 58.1 20.9±0.1° 94 50.5 21.5±0.1° 186 100 23.3±0.1° 39 21.0 24.5±0.1° 42 22.6 ;

[0011] The peak height and relative intensity corresponding to the diffraction angle 2θ in the X-ray powder diffraction pattern of the crystal form II are shown in Table 2:

[0012] Table 2 Peak height and relative intensity corresponding to diffraction angle 2θ

[0013]

[0014]

[0015] Preferably, the infrared absorption spectrum of the crystal form 1 has a characteristic peak at the following position: 3296±2cm -1 、3119±2cm -1 、2985±2cm -1 、1779±2cm -1 、1760±2cm -1 、1645±2cm -1 、1586±2cm -1 、1541±2cm -1 、1273±2cm -1 、1239±2cm -1 、1218±2cm -1 、1185±2cm -1 、1121±2cm -1 、1044±2cm -1 、638±2cm -1 ;

[0016] The infrared absorption spectrum of the crystal form II has characteristic peaks at the following positions: 3317±2cm -1 、3191±2cm -1 、2987±2cm -1 、1736±2cm -1、1666±2cm -1 、1641±2cm -1 、1575±2cm -1 、1530±2cm -1 、1290±2cm -1 、1259±2cm -1 、1224±2cm -1 、1187±2cm -1 、1156±2cm -1 、1045±2cm -1 、639±2cm -1 .

[0017] Preferably, the decomposition temperature of the crystalline form 1 is 203-238°C;

[0018] The decomposition temperature of the crystal form II is 199-230°C.

[0019] Preferably, the thermogravimetric analysis spectrum of the crystal form 1 is a stable straight line in the region of 30-220°C, and the sample begins to decompose after 220°C;

[0020] The thermogravimetric analysis spectrum of the crystal form II is a stable straight line in the region of 30-200°C, and the sample begins to decompose after 200°C.

[0021] The present invention also provides a method for preparing the new crystal form of aztreonam described in the above technical scheme, comprising the following steps:

[0022] Dissolving aztreonam in an organic solvent to obtain an aztreonam solution; the organic solvent is N,N-dimethylacetamide, dimethyl sulfoxide or N,N-dimethylformamide;

[0023] The aztreonam solution and the reverse dissolution agent are mixed to perform dissolution crystallization to obtain a new crystal form of aztreonam; when the reverse dissolution solvent is methanol, anhydrous ethanol or acetonitrile, the new crystal form of aztreonam is crystal form I; when the reverse dissolution solvent is chloroform, the new crystal form of aztreonam is crystal form II.

[0024] Preferably, the dissolving temperature is 40-50°C;

[0025] When the new crystal form of aztreonam is crystal form 1, the mass ratio of aztreonam to the volume ratio of the organic solvent is 1.0-2.0 g:2-5 mL;

[0026] When the new crystal form of aztreonam is crystal form II, the mass of aztreonam and the volume ratio of the organic solvent are 0.39-0.5 g:1-3 mL.

[0027] Preferably, the mixing further comprises:

[0028] Cooling the aztreonam solution; the cooling rate of the cooling is 0.2-1°C / min;

[0029] The solution was kept at a constant temperature after cooling.

[0030] Preferably, the mixing is performed by dripping the anti-solvent into the aztreonam solution; the dripping rate is 0.2-1 mL / min;

[0031] The dissolution and crystallization time is 5 to 8 hours.

[0032] The present invention also provides the use of the new crystal form of aztreonam described in the above technical solution or the new crystal form of aztreonam prepared by the preparation method described in the above technical solution in the preparation of β-lactam antibiotic drugs.

[0033] The invention provides a new crystal form of aztreonam, wherein the new crystal form of aztreonam includes a crystal form 1 or a crystal form 2, and the X-ray powder diffraction pattern of the crystal form 1 is 8.6±0.1°, 9.3±0.1°, 11.2±0.1°, 16.8±0.1°, 17.6±0.1°, 18.6±0.1°, 20.9±0.1°, 21.5±0.1°, 23.3±0.1°, 24.5 ±0.1° has characteristic peaks; the X-ray powder diffraction pattern of the crystal form II has characteristic peaks at diffraction angles 2θ of 9.5±0.1°, 10.3±0.1°, 12.3±0.1°, 15.2±0.1°, 15.7±0.1°, 19.3±0.1°, 20.9±0.1°, 21.9±0.1°, 24.8±0.1°, 27.6±0.1°, and 31.8±0.1°. The interaction between the new crystal form of aztreonam provided by the present invention and water is stronger than that of other crystal forms, thereby improving its water solubility; the solubility of the crystal form I in water at a temperature of 25°C is 1.108g / L, and the solubility of the crystal form II in water at a temperature of 25°C is 1.133g / L. The beta-lactam antibiotic drug prepared by using the new crystal form of aztreonam provided by the invention has high bioavailability, thereby improving the medical value of the drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The XRD spectrum of the aztreonam crystal form 1 prepared in Example 1;

[0035] Figure 2 The DSC spectrum of the aztreonam crystal form 1 prepared in Example 1;

[0036] Figure 3 Thermal decomposition curve of the aztreonam crystal form I prepared in Example 1;

[0037] Figure 4 The infrared spectrum of the aztreonam crystal form 1 prepared in Example 1;

[0038] Figure 5 The XRD spectrum of aztreonam crystalline form II prepared in Example 10;

[0039] Figure 6 The DSC spectrum of aztreonam crystalline form II prepared in Example 10;

[0040] Figure 7 This is a thermal decomposition curve of the second aztreonam crystal form prepared in Example 10;

[0041] Figure 8 This is the infrared spectrum of the aztreonam crystal form II prepared in Example 10;

[0042] Fig. 9 This is the moisture absorption curve of the new crystal form of aztreonam;

[0043] Fig.10 This is a polarizing microscope image of the aztreonam crystal form 1 prepared in Example 1;

[0044] Fig.11 This is a polarizing microscope image of the aztreonam crystal form II prepared in Example 10. DETAILED DESCRIPTION

[0045] The invention provides a new crystal form of aztreonam, which comprises a crystal form one or a crystal form two, and an X-ray powder diffraction pattern of the crystal form one has characteristic peaks at diffraction angles 2θ of 8.6±0.1°, 9.3±0.1°, 11.2±0.1°, 16.8±0.1°, 17.6±0.1°, 18.6±0.1°, 20.9±0.1°, 21.5±0.1°, 23.3±0.1° and 24.5±0.1°.

[0046] In the present invention, the peak height and relative intensity corresponding to the diffraction angle 2θ in the X-ray powder diffraction pattern of the crystal form 1 are preferably as shown in Table 1:

[0047] Table 1 Peak height and relative intensity corresponding to diffraction angle 2θ

[0048] 2θ(°) Peak height Relative strength (%) 8.6±0.1° 29 15.6 9.3±0.1° 21 11.3 11.2±0.1° 103 55.4 16.8±0.1° 82 44.1 17.6±0.1° 27 14.5 18.6±0.1° 108 58.1 20.9±0.1° 94 50.5 21.5±0.1° 186 100 23.3±0.1° 39 21.0 24.5±0.1° 42 22.6

[0049] In the present invention, the infrared absorption spectrum of the crystal form 1 preferably has a characteristic peak at the following position: 3296±2cm -1 、3119±2cm -1 、2985±2cm -1 、1779±2cm -1 、1760±2cm -1 、1645±2cm -1 、1586±2cm -1、1541±2cm -1 、1273±2cm -1 、1239±2cm -1 、1218±2cm -1 、1185±2cm -1 、1121±2cm -1 、1044±2cm -1 、638±2cm -1 .

[0050] In the present invention, the decomposition temperature of the crystal form 1 is preferably 203-238°C, more preferably 205-236°C, and further preferably 206-235°C.

[0051] In the present invention, the thermogravimetric analysis spectrum of the crystal form 1 is preferably a stable straight line in the region of 30 to 220°C, and the sample preferably begins to decompose after 220°C.

[0052] In the present invention, the X-ray powder diffraction pattern of the crystal form II has characteristic peaks at diffraction angles 2θ of 9.5±0.1°, 10.3±0.1°, 12.3±0.1°, 15.2±0.1°, 15.7±0.1°, 19.3±0.1°, 20.9±0.1°, 21.9±0.1°, 24.8±0.1°, 27.6±0.1°, and 31.8±0.1°. In the present invention, the peak height and relative intensity corresponding to the diffraction angle 2θ in the X-ray powder diffraction pattern of the crystal form II are preferably as shown in Table 2:

[0053] Table 2 Peak height and relative intensity corresponding to diffraction angle 2θ

[0054] 2θ(°) Peak height Relative strength (%) 9.5±0.1° 28 14.1 10.3±0.1° 35 17.7 12.3±0.1° 60 30.3 15.2±0.1° 147 74.2 15.7±0.1° 62 31.3 19.3±0.1° 198 100 20.9±0.1° 57 28.8 21.9±0.1° 84 42.4 24.8±0.1° 118 59.6 27.6±0.1° 48 24.2 31.8±0.1° 89 44.9

[0055] In the present invention, the infrared absorption spectrum of the crystal form II has a characteristic peak at the following position: 3317±2cm -1 、3191±2cm -1 、2987±2cm -1 、1736±2cm -1 、1666±2cm -1 、1641±2cm -1 、1575±2cm -1 、1530±2cm -1 、1290±2cm -1 、1259±2cm -1 、1224±2cm -1 、1187±2cm -1 、1156±2cm -1 、1045±2cm -1、639±2cm -1 .

[0056] In the present invention, the decomposition temperature of the second crystal form is preferably 199-230°C, more preferably 200-227°C, and further preferably 202-225°C.

[0057] In the present invention, the thermogravimetric analysis spectrum of the crystal form II is preferably a stable straight line in the region of 30-200°C, and the sample preferably begins to decompose after 200°C.

[0058] The present invention also provides a method for preparing the new crystal form of aztreonam described in the above technical scheme, comprising the following steps:

[0059] Dissolving aztreonam in an organic solvent to obtain an aztreonam solution; the organic solvent is N,N-dimethylacetamide, dimethyl sulfoxide or N,N-dimethylformamide;

[0060] The aztreonam solution and the reverse dissolution agent are mixed to perform dissolution crystallization to obtain a new crystal form of aztreonam; when the reverse dissolution solvent is methanol, anhydrous ethanol or acetonitrile, the new crystal form of aztreonam is crystal form I; when the reverse dissolution solvent is chloroform, the new crystal form of aztreonam is crystal form II.

[0061] The present invention dissolves aztreonam in an organic solvent to obtain an aztreonam solution. In the present invention, the organic solvent is N,N-dimethylacetamide, dimethyl sulfoxide or N,N-dimethylformamide, preferably N,N-dimethylacetamide. In the present invention, the aztreonam is preferably the aztreonam bulk drug produced by Hainan Lingkang Pharmaceutical Co., Ltd.

[0062] In the present invention, when the new crystal form of aztreonam is crystal form one, the mass ratio of aztreonam to the volume ratio of the organic solvent is preferably 1.0-2.0 g: 2-5 mL, more preferably 1.4-1.5 g: 2-5 mL; when the new crystal form of aztreonam is crystal form two, the mass ratio of aztreonam to the volume ratio of the organic solvent is preferably 0.39-0.5 g: 1-3 mL, more preferably 0.39-0.40 g: 1-3 mL.

[0063] In the present invention, the dissolution temperature is preferably 40-50° C., more preferably 45-50° C. In the present invention, the dissolution is preferably carried out under stirring, and the stirring is preferably magnetic stirring. In the present invention, the dissolution time is preferably 13-17 min, more preferably 15 min.

[0064] After obtaining the aztreonam solution, the present invention mixes the aztreonam solution and an anti-solution agent, performs dissolution crystallization, and obtains a new crystal form of aztreonam. In the present invention, when the anti-solution agent is methanol, anhydrous ethanol or acetonitrile, the new crystal form of aztreonam is crystal form one; when the anti-solution agent is chloroform, the new crystal form of aztreonam is crystal form two. In the present invention, the anti-solution agent should not exceed 5 times of the aztreonam solution.

[0065] In the present invention, the mixing step preferably further comprises:

[0066] Cool the aztreonam solution;

[0067] The solution was kept at a constant temperature after cooling.

[0068] In the present invention, the temperature after cooling is preferably 20-30°C, more preferably 22-26°C. In the present invention, the cooling rate of the cooling is preferably 0.2-1°C / min, more preferably 0.5-0.8°C / min. In the present invention, the constant temperature time is preferably 0.5-1h, more preferably 0.6-0.8h.

[0069] In the present invention, the mixing is preferably performed by dripping the anti-solvent into the aztreonam solution. In the present invention, the dripping rate is preferably 0.2 to 1 mL / min, more preferably 0.5 to 0.8 mL / min.

[0070] In the present invention, the temperature of the dissolution crystallization is preferably 20 to 30° C., more preferably 22 to 26° C. In the present invention, when the new crystal form of aztreonam is crystal form I, the time of the dissolution crystallization is preferably 5 to 8 hours, more preferably 6 to 7 hours; when the new crystal form of aztreonam is crystal form II, the time of the dissolution crystallization is preferably 4 to 6 hours, more preferably 4.5 to 5 hours.

[0071] In the present invention, the dissolution crystallization preferably further comprises:

[0072] The system after dissolution and crystallization is subjected to solid-liquid separation to obtain a solid;

[0073] The solid is dried to obtain the new crystalline form of aztreonam.

[0074] In the present invention, the solid-liquid separation is preferably filtration, and the filtration is preferably vacuum filtration.

[0075] In the present invention, when preparing Form 1, the filtration is preferably followed by washing; the washing solvent is preferably anhydrous ethanol or acetonitrile, more preferably anhydrous ethanol.

[0076] In the present invention, the drying temperature is preferably 40-60°C, more preferably 45-55°C, and most preferably 50°C; the drying time is preferably 12-24h, more preferably 15-20h. In the present invention, the drying is preferably carried out in a blast drying oven.

[0077] The preparation method provided by the invention has the advantages of simple operation, stable process, low energy consumption and high economy.

[0078] The present invention also provides the use of the new crystal form of aztreonam described in the above technical solution or the new crystal form of aztreonam prepared by the preparation method described in the above technical solution in the preparation of β-lactam antibiotic drugs.

[0079] In order to further illustrate the present invention, the technical solutions provided by the present invention are described in detail below in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0080] Example 1

[0081] Dissolve 1.5002 g of aztreonam raw material in 2 mL of N,N-dimethylformamide at 40° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0082] The aztreonam solution was cooled to 20°C at a cooling rate of 0.5°C / min and kept at a constant temperature for 0.5h; 25mL of anhydrous ethanol was added dropwise to the aztreonam solution at a dropping rate of 0.5mL / min, and dissolved and crystallized at 20°C for 6h;

[0083] The system after dissolution and crystallization was filtered under reduced pressure (the filter cake was washed with anhydrous ethanol), and the solid obtained by filtration was placed in a 40° C. forced air drying oven and dried for 24 hours to obtain aztreonam crystal form 1.

[0084] Example 2

[0085] Dissolve 1.5002 g of aztreonam raw material in 3 mL of N,N-dimethylformamide at 42° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0086] The aztreonam solution was cooled to 22°C at a cooling rate of 0.8°C / min and kept at a constant temperature for 0.6h; 30mL of anhydrous ethanol was added dropwise to the aztreonam solution at a dropping rate of 0.2mL / min, and dissolved and crystallized at 22°C for 8h;

[0087] The system after dissolution and crystallization was filtered under reduced pressure (the filter cake was washed with anhydrous ethanol), and the solid obtained by filtration was placed in a 50° C. forced air drying oven and dried for 15 hours to obtain aztreonam crystal form 1.

[0088] Example 3

[0089] Dissolve 1.4999 g of aztreonam API in 5 mL of N,N-dimethylformamide at 45° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0090] The aztreonam solution was cooled to 26°C at a cooling rate of 1°C / min and kept at a constant temperature for 0.8h; 25mL of anhydrous ethanol was added dropwise to the aztreonam solution at a dropping rate of 1mL / min, and dissolved and crystallized at 26°C for 7h;

[0091] The system after dissolution and crystallization was filtered under reduced pressure (the filter cake was washed with anhydrous ethanol), and the solid obtained by filtration was placed in a 45° C. forced air drying oven and dried for 20 hours to obtain aztreonam crystal form 1.

[0092] Example 4

[0093] Dissolve 1.5002 g of aztreonam raw material in 4 mL of N,N-dimethylformamide at 48° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0094] The aztreonam solution was cooled to 28°C at a cooling rate of 0.2°C / min and kept at this temperature for 1 hour; 25 mL of acetonitrile was added dropwise to the aztreonam solution at a dropping rate of 0.8 mL / min, and dissolved and crystallized at 28°C for 5 hours;

[0095] The system after dissolution and crystallization was filtered under reduced pressure (the filter cake was washed with acetonitrile), and the solid obtained by filtration was placed in a 55° C. forced air drying oven and dried for 18 hours to obtain aztreonam crystal form 1.

[0096] Example 5

[0097] Dissolve 1.5044 g of aztreonam bulk drug in 3 mL of N,N-dimethylformamide at 50° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0098] The aztreonam solution was cooled to 30°C at a cooling rate of 0.4°C / min and kept at this temperature for 1 hour; 30 mL of acetonitrile was added dropwise to the aztreonam solution at a dropping rate of 0.4 mL / min, and dissolved and crystallized at 30°C for 8 hours;

[0099] The system after dissolution and crystallization was filtered under reduced pressure (the filter cake was washed with acetonitrile), and the solid obtained by filtration was placed in a 60° C. forced air drying oven and dried for 12 hours to obtain aztreonam crystal form 1.

[0100] The appearance of the aztreonam crystal form 1 prepared in Examples 1 to 5 is a white powder. The aztreonam crystal form 1 prepared in Examples 1 to 5 was subjected to XRD detection. The aztreonam crystal form 1 prepared in Examples 1 to 5 had characteristic peaks at diffraction angles 2θ of 8.6±0.1°, 9.3±0.1°, 11.2±0.1°, 16.8±0.1°, 17.6±0.1°, 18.6±0.1°, 20.9±0.1°, 21.5±0.1°, 23.3±0.1°, and 24.5±0.1°. The XRD spectrum of the aztreonam crystal form 1 prepared in Example 1 is as follows: Figure 1 shown.

[0101] The aztreonam crystal form 1 prepared in Examples 1 to 5 was subjected to differential scanning calorimetry (DSC); the DSC spectrum of the aztreonam crystal form 1 prepared in Example 1 is as follows Figure 2 As shown; the particle size of the aztreonam crystal form 1 prepared in Examples 1 to 5 was detected by Malvern laser particle size analyzer; the purity of the aztreonam crystal form 1 prepared in Examples 1 to 5 was detected by high performance liquid chromatography, and the results are listed in Table 3.

[0102] Table 3 Performance parameters of aztreonam crystal form 1 prepared in Examples 1 to 5

[0103] Example Decomposition temperature(℃) <![CDATA[D 50 (μm)]]> purity(%) Yield (%) Example 1 205-235 26.6 99.8 88.9 Example 2 207-234 25.9 99.8 88.8 Example 3 208-238 27.7 99.8 88.7 Example 4 203-236 27.3 99.8 93.6 Example 5 206-235 26.9 99.8 94.7

[0104] The aztreonam crystal form 1 prepared in Example 1 was subjected to thermogravimetric analysis to obtain a thermal decomposition curve as shown in FIG. Figure 3 As shown. Figure 3 It can be seen that there is no weight loss between 30 and 220°C, and decomposition begins to occur after 220°C.

[0105] The aztreonam crystal form 1 prepared in Example 1 was subjected to infrared detection to obtain an infrared spectrum as shown in FIG. Figure 4 As shown. Figure 4 It can be seen that the crystal type 1 is at 3296±2cm -1 、3119±2cm -1 、2985±2cm -1 、1779±2cm -1 、1760±2cm -1 、1645±2cm -1 、1586±2cm -1 、1541±2cm -1 、1273±2cm -1 、1239±2cm -1 、1218±2cm -1 、1185±2cm -1 、1121±2cm -1 、1044±2cm -1、638±2cm -1 There are infrared characteristic peaks at , which are significantly different from the crystal forms reported in other patents.

[0106] The thermogravimetric analysis results of Examples 2 to 5 are consistent with those of Example 1; the infrared detection results of Examples 2 to 5 are consistent with those of Example 1.

[0107] Example 6

[0108] Dissolve 0.4003 g of aztreonam raw material in 1 mL of N,N-dimethylformamide at 40° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0109] The aztreonam solution was cooled to 20°C at a cooling rate of 0.5°C / min and kept at a constant temperature for 0.5h; 25mL of chloroform was added dropwise to the aztreonam solution at a dropping rate of 0.2mL / min, and dissolved and crystallized at 20°C for 5h;

[0110] The system after dissolution and crystallization was filtered under reduced pressure, and the solid obtained by filtration was placed in a 48° C. forced air drying oven and dried for 15 hours to obtain aztreonam crystal form II.

[0111] Example 7

[0112] Dissolve 0.4004 g of aztreonam raw material in 2 mL of N,N-dimethylformamide at 42° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0113] The aztreonam solution was cooled to 23°C at a cooling rate of 0.8°C / min and kept at a constant temperature for 0.6h; 25mL of chloroform was added dropwise to the aztreonam solution at a dropping rate of 0.5mL / min, and dissolved and crystallized at 23°C for 4h;

[0114] The system after dissolution and crystallization was filtered under reduced pressure, and the solid obtained by filtration was placed in a 40° C. forced air drying oven and dried for 18 hours to obtain aztreonam crystal form II.

[0115] Example 8

[0116] Dissolve 0.4001 g of aztreonam raw material in 3 mL of N,N-dimethylformamide at 45° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0117] The aztreonam solution was cooled to 26°C at a cooling rate of 0.2°C / min and kept at this temperature for 1 hour; 15 mL of chloroform was added dropwise to the aztreonam solution at a dropping rate of 1 mL / min, and dissolved and crystallized at 26°C for 4 hours;

[0118] The system after dissolution and crystallization was filtered under reduced pressure, and the solid obtained by filtration was placed in a 53° C. forced air drying oven and dried for 13 hours to obtain aztreonam crystal form II.

[0119] Example 9

[0120] Dissolve 0.4004 g of aztreonam raw material in 2 mL of N,N-dimethylformamide at 48° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0121] The aztreonam solution was cooled to 28°C at a cooling rate of 1°C / min and kept at a constant temperature for 1 hour; 15 mL of chloroform was added dropwise to the aztreonam solution at a dropping rate of 0.4 mL / min, and dissolved and crystallized at 28°C for 6 hours;

[0122] The system after dissolution and crystallization was filtered under reduced pressure, and the solid obtained by filtration was placed in a 58° C. forced air drying oven and dried for 16 hours to obtain aztreonam crystal form II.

[0123] Example 10

[0124] Dissolve 0.3998 g of aztreonam raw material in 1 mL of N,N-dimethylformamide at 50° C. (magnetic stirring for 15 min) to obtain an aztreonam solution;

[0125] The aztreonam solution was cooled to 30°C at a cooling rate of 0.4°C / min and kept at a constant temperature for 0.8h; 25mL of chloroform was added dropwise to the aztreonam solution at a dropping rate of 0.8mL / min, and dissolved and crystallized at 30°C for 5h;

[0126] The system after dissolution and crystallization was filtered under reduced pressure, and the solid obtained by filtration was placed in a 60° C. forced air drying oven and dried for 12 hours to obtain aztreonam crystal form II.

[0127] The appearance of the aztreonam crystal form II prepared in Examples 6 to 10 is a white powder. The aztreonam crystal form II prepared in Examples 6 to 10 was subjected to XRD detection. The aztreonam crystal form II prepared in Examples 6 to 10 had characteristic peaks at diffraction angles 2θ of 9.5±0.1°, 10.3±0.1°, 12.3±0.1°, 15.2±0.1°, 15.7±0.1°, 19.3±0.1°, 20.9±0.1°, 21.9±0.1°, 24.8±0.1°, 27.6±0.1°, and 31.8±0.1°. The XRD spectrum of the aztreonam crystal form II prepared in Example 10 is as follows: Figure 5 shown.

[0128] The aztreonam crystal form II prepared in Examples 6 to 10 was subjected to differential scanning calorimetry (DSC); the DSC spectrum of the aztreonam crystal form II prepared in Example 10 is as follows Figure 6 As shown; the particle size of the aztreonam crystal form II prepared in Examples 6 to 10 was detected by Malvern laser particle size analyzer; the purity of the aztreonam crystal form II prepared in Examples 6 to 10 was detected by high performance liquid chromatography, and the results are listed in Table 4.

[0129] Table 4 Performance parameters of aztreonam crystal form II prepared in Examples 6 to 10

[0130]

[0131]

[0132] Thermogravimetric analysis was performed on the aztreonam crystal form II prepared in Example 10 to obtain a thermal decomposition curve as shown in FIG. Figure 7 As shown. Figure 7 It can be seen that there is no weight loss between 30 and 200°C, and decomposition begins to occur after 200°C.

[0133] The aztreonam crystal form II prepared in Example 10 was subjected to infrared detection to obtain an infrared spectrum as shown in FIG. Figure 8 As shown. Figure 8 It can be seen that the crystal type II is at 3317±2cm -1 、3191±2cm -1 、2987±2cm -1 、1736±2cm -1 、1666±2cm -1 、1641±2cm -1 、1575±2cm -1 、1530±2cm -1 、1290±2cm -1 、1259±2cm -1 、1224±2cm -1 、1187±2cm -1 、1156±2cm -1 、1045±2cm -1 、639±2cm -1 There are characteristic peaks at , which are significantly different from the crystal forms reported in existing patents.

[0134] The thermogravimetric analysis results of Examples 6 to 9 are consistent with those of Example 10; the infrared detection results of Examples 6 to 9 are consistent with those of Example 10.

[0135] Stability test of new crystal form of aztreonam:

[0136] The aztreonam crystal form 1 prepared in Example 1 and the aztreonam crystal form 2 prepared in Example 10 were placed in different relative humidity environments, and the quality change of the aztreonam new crystal form was detected. The results are listed in Table 5.

[0137] Table 5 Hygroscopicity of the new crystal form of aztreonam in different humidity environments

[0138]

[0139]

[0140] The aztreonam crystal form 1 prepared in Example 1 and the aztreonam crystal form 2 prepared in Example 10 were stored at a relative humidity of 75±5% for 30 days to observe changes in their color and purity. The results are listed in Table 6.

[0141] Table 6 Changes of the new crystal form of aztreonam in an environment with a relative humidity of 75±5%

[0142]

[0143] Combined with Table 5, a new crystal form of aztreonam was plotted for moisture absorption, as shown in FIG. Fig. 9 Combining Table 5 and Fig. 9 It can be seen that both crystal form 1 and crystal form 2 have good hygroscopic stability. Crystal form 1 absorbs no more than 3% of moisture at a relative humidity of 95%; and crystal form 2 absorbs no more than 2.5% of moisture at a relative humidity of 95%.

[0144] According to Table 6, when Form I and Form II are stored in an environment with a relative humidity of 75±5%, the purity remains almost unchanged even after storage for 30 days, which proves that both forms have good stability, Form I is a stable form with good chemical stability, and Form II is a metastable form.

[0145] The new crystal form of aztreonam provided by the invention is suitable for the manufacture and long-term storage of pharmaceutical preparations.

[0146] Solubility test of new crystal form of aztreonam:

[0147] The aztreonam crystal form 1 prepared in Example 1 and the aztreonam crystal form 2 prepared in Example 10 were gradually dissolved in water at 25° C. until saturation. The solubility of the aztreonam crystal form 1 was 1.108 g / L, and the solubility of the aztreonam crystal form 1 was 1.133 g / L.

[0148] The aztreonam crystal form 1 prepared in Example 1 and the aztreonam crystal form 2 prepared in Example 10 were detected using a polarizing microscope, and a polarizing microscope image of the aztreonam crystal form 1 was obtained as shown in Fig.10 As shown; the obtained aztreonam crystal polarizing microscope image is as shown Fig.11 shown.

[0149] Depend on Fig.10 and Fig.11 It can be seen that crystal form 1 is irregular block-shaped and crystal form 2 is irregular flake-shaped.

[0150] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. a new crystal form of aztreonam one, the X-ray powder diffraction pattern of the crystal form one is that 8.6 ± 0.1 °, 9.3 ± 0.1 °, 11.2 ± 0.1 °, 16.8 ± 0.1 °, 17.6 ± 0.1 °, 18.6 ± 0.1 °, 20.9 ± 0.1 °, 21.5 ± 0.1 °, 23.3 ± 0.1 °, 24.5 ± 0.1 ° have characteristic peaks at diffraction angles 2 θ.

2. The new crystal form of aztreonam according to claim 1, It is characterized in that The peak height and relative intensity corresponding to the diffraction angle 2θ in the X-ray powder diffraction pattern of the crystal form 1 are shown in Table 1: Table 1 Peak height and relative intensity corresponding to diffraction angle 2θ 。 3. Aztreonam new crystal form one according to claim 1, It is characterized in that The infrared absorption spectrum of the crystal form 1 has characteristic peaks at the following positions: 3296±2cm -1 、3119±2cm -1 、2985±2cm -1 、1779±2cm -1 、1760±2cm -1 、1645±2cm -1 、1586±2cm -1 、1541±2cm -1 、1273±2cm -1 、1239±2cm -1 、1218±2cm -1 、1185±2cm -1 、1121±2cm -1 、1044±2cm -1 、638±2cm -1 .

4. The new crystal form of aztreonam according to claim 1, It is characterized in that The decomposition temperature of the crystal form 1 is 203-238°C.

5. Aztreonam new crystal form one according to claim 1, It is characterized in that The thermogravimetric analysis spectrum of the crystal form 1 is a stable straight line in the region of 30-220°C, and the sample begins to decompose after 220°C.

6. The method for preparing the new crystal form 1 of aztreonam according to any one of claims 1 to 5, The following steps are involved: Dissolving aztreonam in an organic solvent to obtain an aztreonam solution; the organic solvent is N,N-dimethylacetamide, dimethyl sulfoxide or N,N-dimethylformamide; The aztreonam solution and the reverse dissolution agent are mixed to perform dissolution crystallization to obtain a new crystal form of aztreonam; the reverse dissolution solvent is methanol, anhydrous ethanol or acetonitrile.

7. The preparation method according to claim 6, It is characterized in that The dissolving temperature is 40-50°C; The mass of the aztreonam and the volume ratio of the organic solvent are 1.0-2.0 g: 2-5 mL.

8. The preparation method according to claim 6, It is characterized in that The mixing also includes: The aztreonam solution is cooled at a rate of 0.2 to 1°C / min; The solution was kept at a constant temperature after cooling.

9. The preparation method according to claim 6 or 8, It is characterized in that The mixing is to drop the anti-solution agent into the aztreonam solution; the rate of the dropwise addition is 0.2-1 mL / min; The dissolution and crystallization time is 5 to 8 hours.

10. Use of the new crystal form of aztreonam described in any one of claims 1 to 5 or the new crystal form of aztreonam prepared by the preparation method described in any one of claims 6 to 9 in the preparation of β-lactam antibiotics.

Citation Information

Patent Citations

  • Aztreonam compound, as well as preparation method and pharmaceutical composition thereof

    CN103232449A

  • Aztreonam compound serving as sterilization medicine and preparation method thereof

    CN105001215A

  • Anti-infective aztreonam composition

    CN105055323A

  • Antibacterial drug aztreonam composition

    CN105055406A

  • Novel aztreonam compound

    CN105085511A